Therapeutic Evaluation of Unani Formulations in the Management of Iltihab al-Shuab Muzmin (Chronic Bronchitis) : A Randomized Single Blind Parallel Group Comparative Study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
This study is a randomized, single-blind, parallel-group comparative clinical trial conducted at Ajmal Khan Tibbiya College and Hospital as part of the M.D. (Moalajat) program. The trial aims to evaluate and compare the therapeutic efficacy of two selected Unani formulations in the management of Iltihab al-Shu’ab Muzmin (Chronic Bronchitis), a clinical entity corresponding to chronic bronchitis under COPD. Participants diagnosed with chronic bronchitis will be randomly allocated into two groups and treated with different polyherbal decoctions. The first formulation contains Zoofa Khushk, Hulba, Irsa, Asl-us-Soos, Anjeer Zard, and Maweez Munaqqa, while the second formulation includes Asl-us-Soos, Parsiaoshan, Zoofa Yabis, and Sapistan. The study is designed to scientifically assess and compare their effects in relieving key symptoms such as cough, sputum production, breathlessness, and wheezing, based on predefined clinical parameters. The objective is to generate evidence regarding their anti-inflammatory, expectorant, mucolytic, bronchodilator, and concoctive properties in the management of chronic bronchitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Participant Blinded
入排标准
- 年龄范围
- 30.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients in the age group 30-65 years.
- •Patients of either sex.
- •Patient presenting cough with expectoration of at least three months of two consecutive years.
- •Patient with FEV1 greater than or equal to 80 percent predicted (GOLD 1) and FEV1 more than 50 percent and less than 80 percent predicted (GOLD 2) , FEV1/FVC ratio less than 70 percent of predicted value.
- •Prediabetic and diabetics (HbA1c less than 7%) Patient of chronic bronchitis in a stable condition without any signs of acute exacerbation of disease Patient underwent atleast 2 weeks washout period before randomization Those who give written consent.
排除标准
- •Acute exacerbation of disease Bronchial Asthma Patient demonstrating any radiographic evidence of infiltrates or pulmonary patches on Chest Xray Cor Pulmonale and Congestive Heart Failure, Pregnant & lactating mothers Patient having uncontrolled hypertension (BP greater then or equal to 160 by 100 mm Hg) , CLD, CKD Patient on oxygen therapy Obese Patients (BMI more than 30 kg per m2) Patients who fail to give consent Patients who fail to follow up Mentally retarded persons.
研究者
Asra Sadique
Ajmal Khan Tibbiya College